The study and its comparison
A secondary analysis included 1,202 dermatology-clinic participants without diabetes at baseline, randomized to selenium 200 micrograms daily or placebo. Average follow-up was 7.7 years. [1]
Diabetes developed in 58 selenium recipients and 39 placebo recipients. The reported hazard ratio was 1.55, with a 95-percent confidence interval of 1.03–2.33. [1]
What the finding establishes
Diabetes was a secondary endpoint; diagnoses were self-reported and mostly validated. Participants were predominantly older and white. These limitations matter, but the result cannot be turned into a prevention claim. Funding and conflicts were not established from the abstract. [1]
A hypothetical distinction
Imagine a plausible glucose mechanism is followed by more clinical diagnoses. The clinical result must remain visible.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.